CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalation...
Phase 1, Phase 2
San Marcos, California, United States and 9 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
San Diego, California, United States and 107 other locations
The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer...
San Diego, California, United States and 4 other locations
single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate...
Phase 2
La Jolla, California, United States and 2 other locations
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...
Phase 1, Phase 2
La Jolla, California, United States and 22 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
San Diego, California, United States and 131 other locations
of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate...
Phase 2
San Diego, California, United States and 16 other locations
enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate...
Phase 1, Phase 2
San Diego, California, United States and 23 other locations
impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate...
Phase 2
La Jolla, California, United States and 3 other locations
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
Phase 1
San Diego, California, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal